Afuco™ Anti-Human DKK1 ADCC Therapeutic Antibody (BHQ880), ADCC Enhanced
Anti-DKK1 ADCC Enhanced Antibody (BHQ880) is an ADCC enhanced antibody produced by our Afuco™ platform. BHQ880 is a human neutralizing IgG1 anti-DKK1 monoclonal antibody, that is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myeloma activity. BHQ880 in combination with zoledronic acid and anti-myeloma therapy was well tolerated and demonstrated potential clinical activity in patients with relapsed or refractory multiple myeloma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-202CL |
| Pricing | Inquiry |
| Host | Human |
| Target | DKK1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C |